Sandoz Agrees to $450 Million Settlement in Generic Drug Antitrust Litigation
Sandoz settles remaining government antitrust claims for $450 million amid H1 2026 profit plunge
Long-running generic drug antitrust pricing litigation has reached a definitive resolution for Sandoz, with the manufacturer clearing its remaining obligations to government entities across the United States. Sandoz has agreed to settle remaining government claims in the long-running generic drug antitrust pricing litigation, agreeing to pay $450 million to resolve disputes spanning 43 US states and territories. The deal settles the government side of the antitrust pricing claims without any admission of wrongdoing by Sandoz, closing a chapter that has encompassed multiple rounds of negotiation and legal action over the company’s generic portfolio.
The financial architecture of the settlement reflects the complexity of aligning payments across dozens of jurisdictions, with costs spread out rather than front-loaded. Under the agreement, Sandoz will remit $400 million distributed over seven years beginning in 2027, while an additional ~$50 million is allocated to prior settlors. This structure defers a substantial portion of the liability into future cash flows, though it also confirms the magnitude of the exposure involved in the antitrust cases that had constrained the company’s strategic flexibility for years.
The settlement coincides with a period of intense financial pressure already documented in Sandoz’s operating results. In the first half of 2026, Sandoz saw profits plummet by 70% to $109M as the company faced around $480 million in US legal costs. The settlement amount sits directly within that earlier legal toll, indicating that the $450 million payment is part of a much larger hit; between fines, settlements, and accumulated costs reported in H1 2026, the antitrust litigation had already extracted roughly half a billion dollars before this resolution formally ended the claims.
Sandoz’s balance sheet shows a sharp divergence between revenue performance and net income during this period, highlighting that the primary headwind came from enforcement costs rather than market demand. Turnover grew 10% in USD to $5.76B over the same half-year window, yet the surge in top-line sales was completely absorbed by litigation expenses. This dynamic underscores a company that is generating operational growth but remains financially tethered to the defense of its pricing practices against US regulators.
By resolving all remaining government claims, Sandoz removes the immediate uncertainty surrounding the antitrust pricing cases and frees capital previously earmarked for legal contingencies. With the settlement agreed and the litigation tail risk mitigated, the company can now shift resources away from a regulatory defense posture that has already inflicted severe damage on profitability. The end of these claims marks a transition point for Sandoz: the litigation imposed hundreds of millions in costs and halved profits in a single year, but closing the file allows the manufacturer to move past the antitrust battles that have dominated its recent financial reporting.